Full Year 2025 Fisher & Paykel Healthcare Corporation Ltd Earnings Call Transcript
Key Points
- Fisher & Paykel Healthcare Corp Ltd (FSPKF) reported a 16% increase in operating revenue, reaching $2.02 billion for the full year.
- Net profit after tax rose by 43% to $377.2 million, showcasing strong financial performance.
- The company successfully launched new products, including the Nova Nasal mask and Airvo 3, contributing to growth in both hospital and homecare segments.
- Gross margin improved by 181 basis points, driven by manufacturing and overhead efficiencies.
- Operating cash flow increased by 28% to $549 million, reflecting robust profit growth and efficient cash management.
- Global tariffs are expected to impact gross margin by approximately 75 basis points annually, posing a challenge to margin improvement.
- The company faces variability in hospital revenue due to seasonal respiratory hospitalizations, which could affect financial outcomes.
- Operating expenses grew by 10%, which, although expected, indicates rising costs that need to be managed.
- The OSA mask revenue growth slowed in the second half due to competitive pressures, highlighting market challenges.
- The company anticipates a longer timeline to achieve its target gross margin of 65% due to ongoing tariff impacts.
Welcome to the Fisher & Paykel Healthcare's results conference call. My name is Justin, and I will be your operator for today's call. (Operator Instructions) Please note, this conference call is being recorded.
I'd now like to turn the call over to Marcus Driller, VP Corporate.
Thank you, Justin. Well, good morning, everyone, and welcome to the conference call for Fisher & Paykel Healthcare's full-year results for the 2025 financial year. On the call today are Lewis Gradon, Managing Director and Chief Executive Officer; Lyndal York, Chief Financial Officer; Andy Niccol, our Chief Operating Officer; Justin Callahan, VP of Sales and Marketing; and Andrew Somervell, our VP of Products and Technology.
Lewis and Lyndal will first provide an overview of the results, and then we'll move on to questions for the team. We will be discussing our results for the 12 months ended March 31, 2025. Earlier today, we provided our 2025 annual report, including
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
